FDA Schedules Biologics Specification Workshop
This article was originally published in The Pink Sheet Daily
The workshop is part of a series of activities designed to recommend a comprehensive specification process from scratch rather than amend current practices. FDA has said release of a follow-on biologics guidance is on hold until after a forum on the subject is held.
You may also be interested in...
A public scientific workshop is planned for late summer; timing or content of a guidance cannot be predicted until after the meeting, Acting Commissioner Crawford tells Senate Judiciary Committee. Sen. Schumer expresses concern that progress towards "generic" biologics is "slowing."
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states